Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 12:27PM ET
1.87
Dollar change
-0.12
Percentage change
-5.81
%
Index- P/E- EPS (ttm)-2.00 Insider Own2.75% Shs Outstand27.52M Perf Week-30.93%
Market Cap51.32M Forward P/E- EPS next Y-0.73 Insider Trans0.00% Shs Float26.76M Perf Month30.42%
Income-30.55M PEG- EPS next Q-0.21 Inst Own6.16% Short Float9.42% Perf Quarter75.94%
Sales0.00M P/S- EPS this Y65.38% Inst Trans-19.89% Short Ratio0.92 Perf Half Y59.40%
Book/sh-0.51 P/B- EPS next Y37.61% ROA-109.80% Short Interest2.52M Perf Year11.01%
Cash/sh0.53 P/C3.54 EPS next 5Y- ROE-555.68% 52W Range0.81 - 3.02 Perf YTD-5.33%
Dividend Est.- P/FCF- EPS past 5Y19.62% ROI- 52W High-38.25% Beta2.31
Dividend TTM- Quick Ratio0.85 Sales past 5Y-39.15% Gross Margin- 52W Low130.82% ATR (14)0.28
Dividend Ex-Date- Current Ratio0.85 EPS Y/Y TTM17.77% Oper. Margin- RSI (14)47.92 Volatility15.70% 13.61%
Employees14 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.50
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-2.25% Payout- Rel Volume1.03 Prev Close1.98
Sales Surprise- EPS Surprise-37.14% Sales Q/Q- EarningsNov 14 BMO Avg Volume2.75M Price1.87
SMA20-9.48% SMA5020.48% SMA20034.07% Trades Volume1,356,833 Change-5.81%
Date Action Analyst Rating Change Price Target Change
May-28-21Upgrade Gabelli & Co Sell → Hold
Mar-15-21Upgrade H.C. Wainwright Neutral → Buy $2.50
Jun-02-20Downgrade RBC Capital Mkts Outperform → Sector Perform $7 → $2
Jan-21-20Downgrade Gabelli & Co Buy → Sell
Dec-11-19Downgrade SVB Leerink Outperform → Mkt Perform
Jun-21-19Initiated H.C. Wainwright Buy $17
Nov-21-24 08:30AM
Nov-15-24 02:10AM
Nov-14-24 07:00AM
Nov-11-24 08:00AM
Oct-28-24 10:19AM
07:49AM Loading…
07:49AM
05:00AM
Oct-25-24 11:03AM
Oct-10-24 08:30AM
Oct-09-24 05:00PM
Sep-24-24 10:33AM
Sep-10-24 07:00AM
Sep-06-24 04:30PM
Aug-17-24 08:09AM
Aug-14-24 07:00AM
08:18AM Loading…
Aug-10-24 08:18AM
Aug-07-24 04:30PM
Aug-06-24 05:30PM
Aug-02-24 08:00AM
Jul-22-24 07:30AM
Jun-21-24 08:00AM
Jun-05-24 08:00AM
May-31-24 08:00AM
May-14-24 08:21AM
May-13-24 10:49PM
11:53AM
07:00AM
May-06-24 08:00AM
Apr-29-24 08:00AM
Apr-02-24 10:22AM
12:09AM Loading…
Mar-29-24 12:09AM
Mar-28-24 11:53AM
07:00AM
Mar-21-24 04:30PM
Mar-15-24 08:00AM
Mar-07-24 07:57AM
Mar-06-24 08:00AM
Feb-01-24 03:03PM
Jan-30-24 07:00AM
Dec-04-23 08:00AM
Nov-15-23 12:22PM
12:08AM
Nov-14-23 07:00AM
Nov-07-23 08:30AM
Oct-24-23 08:00AM
Oct-12-23 09:15AM
Aug-11-23 10:10PM
07:00AM
Aug-04-23 05:00PM
Jun-27-23 09:50AM
Jun-21-23 08:35AM
Jun-12-23 06:23PM
May-12-23 07:00AM
May-10-23 09:16AM
Apr-20-23 05:00PM
Apr-13-23 12:00PM
Mar-18-23 02:06AM
Mar-16-23 09:16PM
07:00AM
Mar-09-23 05:00PM
Jan-11-23 06:00PM
Dec-15-22 08:00AM
Nov-10-22 07:00AM
Nov-03-22 08:00AM
Oct-20-22 07:30AM
Oct-17-22 05:19PM
Sep-19-22 07:30AM
Sep-07-22 09:15AM
Sep-01-22 04:15PM
Aug-17-22 09:45AM
Aug-16-22 09:00PM
Aug-12-22 07:00AM
Jul-11-22 02:31PM
07:30AM
Jul-06-22 04:30PM
Jun-14-22 05:00PM
May-13-22 07:00AM
May-11-22 08:00AM
Apr-25-22 05:06PM
Mar-28-22 10:19AM
07:00AM
Mar-21-22 08:00AM
Mar-10-22 08:00AM
Feb-08-22 05:00PM
Dec-14-21 04:30PM
07:12AM
Dec-13-21 08:00AM
Nov-22-21 10:00AM
Nov-12-21 07:00AM
Nov-05-21 07:00AM
Oct-04-21 02:58PM
01:28PM
12:33PM
11:05AM
10:45AM
10:00AM
09:40AM
08:36AM
07:30AM
05:34AM
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dunne Michael W.DirectorDec 22 '23Buy1.4025,00035,000113,754Dec 27 09:00 AM
Dunne Michael W.DirectorDec 18 '23Buy1.8410,00018,44288,754Dec 19 04:15 PM